STAT

STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment

STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatmentWorldPing

Tenax Therapeutics will soon report results from a Phase 3 study that is one of the biggest binary biotech stock events remaining in the sector this year.

This is a short WorldPing brief. The full report was published by STAT.

Read the full report at STAT

Related news